• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Geographic Atrophy GA Market

    ID: MRFR/HC/14260-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    US Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) and By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Geographic Atrophy GA Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    US Geographic Atrophy GA Market Summary

    The United States Geographic Atrophy market is projected to grow significantly, reaching 12.5 USD billion by 2035.

    Key Market Trends & Highlights

    US Geographic Atrophy GA Key Trends and Highlights

    • The market valuation for Geographic Atrophy in the United States is estimated at 5.75 USD billion in 2024.
    • From 2025 to 2035, the market is expected to grow at a compound annual growth rate of 7.31 percent.
    • By 2035, the market for Geographic Atrophy is anticipated to reach 12.5 USD billion, indicating robust growth potential.
    • Growing adoption of advanced treatment options due to increasing prevalence of age-related macular degeneration is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.75 (USD Billion)
    2035 Market Size 12.5 (USD Billion)
    CAGR (2025-2035) 7.31%

    Major Players

    Genentech, Novartis, Santen Pharmaceutical, Zymeworks, Iveric Bio, EyePoint Pharmaceuticals, Bausch Health, Regeneron Pharmaceuticals, Adaptimmune, Apellis Pharmaceuticals, Amgen, Roche, AbbVie, Alkeus Pharmaceuticals, Eyenovia

    US Geographic Atrophy GA Market Trends

    The US Geographic Atrophy (GA) market is currently experiencing significant transformation driven by advancements in treatment options and increasing awareness of the disease. One of the key market drivers is the rising prevalence of age-related macular degeneration (AMD), particularly among the aging population. The Centers for Disease Control and Prevention (CDC) notes that the incidence of AMD is projected to rise sharply as the baby boomer generation ages, leading to a greater need for effective management strategies for GA.

    There are notable opportunities to be explored within this market, particularly in the development of innovative therapies and technologies.Gene therapy and retinal implants are gaining traction as potential treatments that may offer hope to patients suffering from GA. As research continues, pharmaceutical and biotechnological companies are focusing on clinical trials aimed at demonstrating the efficacy of new treatment modalities, thus expanding the therapeutic landscape for geographic atrophy.

    In recent times, there is a growing emphasis on early diagnosis and preventive care for GA. The integration of advanced diagnostic technologies such as optical coherence tomography (OCT) has improved detection rates, enabling earlier intervention. Moreover, educational initiatives aimed at both healthcare professionals and patients are helping to enhance awareness regarding the symptoms and risk factors associated with GA.

    This increased understanding is crucial as it encourages timely medical consultations, potentially leading to better outcomes for patients. Overall, the US Geographic Atrophy market is characterized by a convergence of technological advancements, demographic changes, and an enhanced focus on early detection, marking a dynamic shift in how this eye condition is managed and treated in the coming years.

    US Geographic Atrophy GA Market Drivers

    Market Segment Insights

    Get more detailed insights about US Geographic Atrophy GA Market Research Report — Global Forecast till 2035

    Regional Insights

    Key Players and Competitive Insights

    The US Geographic Atrophy GA market is witnessing significant evolution, propelled by advancements in research and increasing investments in the development of innovative therapies aimed at slowing disease progression. Geographic Atrophy, a progressive condition linked with age-related macular degeneration, presents both challenges and opportunities for pharmaceutical companies focusing on ophthalmology. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all vying to capture market share through novel treatment options and strategic partnerships.

    This dynamic environment is further influenced by regulatory pathways, reimbursement policies, and the growing emphasis on patient-centric care, driving companies to enhance their product offerings and operational efficiency to address unmet medical needs.

    Genentech has established a formidable presence in the US Geographic Atrophy GA market, focusing on research-driven initiatives aimed at developing treatments that address the complexity of this condition. The company's strength lies in its robust pipeline and commitment to innovative therapies, leveraging its extensive experience in the ophthalmology sector. Genentech’s strategic collaborations and partnerships contribute to its capability in exploring cutting-edge solutions for geographic atrophy, emphasizing the importance of clinical trials that incorporate patient feedback.

    The company’s established brand reputation enhances its competitive edge, enabling it to effectively engage with healthcare providers and patients while navigating the regulatory landscape to expedite the availability of its treatment options.

    Novartis is another key player in the US Geographic Atrophy GA market, known for its diverse portfolio that includes therapies specifically targeting ocular conditions. With a well-established presence in the pharmaceutical landscape, Novartis leverages its research and development expertise to enhance treatment protocols and improve patient outcomes in geographic atrophy management. The company’s strengths are further bolstered by its strategic mergers and acquisitions that expand its capabilities and market reach. Key products in Novartis’ pipeline demonstrate a strong focus on innovative approaches to addressing geographic atrophy, and the company's commitment to patient-centric solutions enables it to maintain competitive advantage.

    Through its extensive distribution network and engagement with stakeholders, Novartis effectively positions itself as a leader in delivering effective therapies for geographic atrophy in the US market.

    Key Companies in the US Geographic Atrophy GA Market market include

    Industry Developments

    The US Geographic Atrophy (GA) Market has seen significant developments recently. In April 2023, Iveric Bio announced positive results from its Phase 3 trials for Zimura, a novel treatment targeting GA, which has since garnered attention for its therapeutic potential. In May 2023, Apellis Pharmaceuticals also reported promising data for Syfovre, its innovative therapy for GA, indicating substantial strides in the treatment landscape.

    Meanwhile, Genentech is actively advancing its pipeline with new compounds, focusing on innovative approaches to address retinal diseases, which has influenced market dynamics. In terms of acquisitions, in August 2023, Novartis completed its acquisition of AveXis, enhancing its capabilities in gene therapies, which may have implications for future GA treatment modalities.

    The market valuation for companies within the GA sector, including EyePoint Pharmaceuticals and Regeneron Pharmaceuticals, has experienced overall growth driven by advancements in Research and Development and positive clinical trial outcomes. Regulatory changes focusing on accelerated approval pathways have also fueled investor interest and market expansion, laying a promising foundation for future innovations in the US Geographic Atrophy Market.

    Market Segmentation

    Geographic Atrophy GA Market Age Group Outlook

    • Above 60 Years
    • Above 75 Years

    Geographic Atrophy GA Market Diagnosis Outlook

    • Fundus Autofluorescence
    • Optical Coherence Tomography Angiography
    • Multifocal Electroretinography

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 5.29(USD Billion)
    MARKET SIZE 2024 5.75(USD Billion)
    MARKET SIZE 2035 12.5(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.314% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Genentech, Novartis, Santen Pharmaceutical, Zymeworks, Iveric Bio, EyePoint Pharmaceuticals, Bausch Health, Regeneron Pharmaceuticals, Adaptimmune, Apellis Pharmaceuticals, Amgen, Roche, AbbVie, Alkeus Pharmaceuticals, Eyenovia
    SEGMENTS COVERED Age Group, Diagnosis, Therapeutic Agents Clinical Phase
    KEY MARKET OPPORTUNITIES Increasing aged population, Advancements in diagnostic tools, Growing demand for innovative therapies, Expansion of clinical trial pipelines, Rising awareness and education programs
    KEY MARKET DYNAMICS Increasing elderly population, Rising awareness and diagnosis, Limited treatment options, High unmet medical needs, Growing investment in research
    COUNTRIES COVERED US

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected overall market size of the US Geographic Atrophy GA Market in 2024?

    The expected overall market size of the US Geographic Atrophy GA Market in 2024 is valued at 5.75 billion USD.

    What will the market size of the US Geographic Atrophy GA Market be in 2035?

    In 2035, the market size of the US Geographic Atrophy GA Market is expected to reach 12.5 billion USD.

    What is the expected CAGR for the US Geographic Atrophy GA Market from 2025 to 2035?

    The expected CAGR for the US Geographic Atrophy GA Market from 2025 to 2035 is 7.314%.

    What is the market size for the age group above 60 years in 2024?

    For the age group above 60 years, the market size is valued at 3.45 billion USD in 2024.

    What will the market size for the age group above 75 years be in 2035?

    In 2035, the market size for the age group above 75 years is expected to reach 5.0 billion USD.

    Who are the major players in the US Geographic Atrophy GA Market?

    Key players in the US Geographic Atrophy GA Market include Genentech, Novartis, Santen Pharmaceutical, and Regeneron Pharmaceuticals.

    What are the growth opportunities in the US Geographic Atrophy GA Market?

    The growth opportunities in the US Geographic Atrophy GA Market are driven by an increasing elderly population and advancements in treatment strategies.

    How is the market for US Geographic Atrophy GA expected to change due to regional trends?

    Regional trends indicate significant growth in the US due to an aging population and increased awareness of ophthalmic conditions.

    What is the projected market size for the age group above 60 years in 2035?

    The projected market size for the age group above 60 years is anticipated to be 7.5 billion USD in 2035.

    What challenges does the US Geographic Atrophy GA Market face going forward?

    The market faces challenges such as regulatory hurdles and competition in treatment innovations.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. US Geographic Atrophy GA Market, BY Age Group (USD Billion)
    45. Above 60 Years
    46. Above 75 Years
    47. US Geographic Atrophy GA Market, BY Diagnosis (USD Billion)
    48. Fundus Autofluorescence
    49. Optical Coherence Tomography Angiography
    50. Multifocal Electroretinography
    51. US Geographic Atrophy GA Market, BY Therapeutic Agents Clinical Phase (USD Billion)
    52. Late-Stage
    53. Phase II
    54. Phase I
    55. Pre-Clinical Stage
    56. Discovery Candidates
    57. Competitive Landscape
    58. Overview
    59. Competitive Analysis
    60. Market share Analysis
    61. Major Growth Strategy in the Geographic Atrophy GA Market
    62. Competitive Benchmarking
    63. Leading Players in Terms of Number of Developments in the Geographic Atrophy GA Market
    64. Key developments and growth strategies
    65. New Product Launch/Service Deployment
    66. Merger & Acquisitions
    67. Joint Ventures
    68. Major Players Financial Matrix
    69. Sales and Operating Income
    70. Major Players R&D Expenditure. 2023
    71. Company Profiles
    72. Genentech
    73. Financial Overview
    74. Products Offered
    75. Key Developments
    76. SWOT Analysis
    77. Key Strategies
    78. Novartis
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Santen Pharmaceutical
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Zymeworks
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Iveric Bio
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. EyePoint Pharmaceuticals
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Bausch Health
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Regeneron Pharmaceuticals
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Adaptimmune
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Apellis Pharmaceuticals
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Amgen
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Roche
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. AbbVie
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Alkeus Pharmaceuticals
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Eyenovia
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. US Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD Billions)
    165. US Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2035 (USD Billions)
    166. US Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019-2035 (USD Billions)
    167. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    168. ACQUISITION/PARTNERSHIP
    169. MARKET SYNOPSIS
    170. US GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY AGE GROUP
    171. US GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY DIAGNOSIS
    172. US GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY THERAPEUTIC AGENTS CLINICAL PHASE
    173. KEY BUYING CRITERIA OF GEOGRAPHIC ATROPHY GA MARKET
    174. RESEARCH PROCESS OF MRFR
    175. DRO ANALYSIS OF GEOGRAPHIC ATROPHY GA MARKET
    176. DRIVERS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    177. RESTRAINTS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    178. SUPPLY / VALUE CHAIN: GEOGRAPHIC ATROPHY GA MARKET
    179. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2025 (% SHARE)
    180. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2019 TO 2035 (USD Billions)
    181. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    182. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    183. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2025 (% SHARE)
    184. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019 TO 2035 (USD Billions)
    185. BENCHMARKING OF MAJOR COMPETITORS

    US Geographic Atrophy GA Market Segmentation

     

     

     

    • Geographic Atrophy GA Market By Age Group (USD Billion, 2019-2035)

      • Above 60 Years
      • Above 75 Years

     

    • Geographic Atrophy GA Market By Diagnosis (USD Billion, 2019-2035)

      • Fundus Autofluorescence
      • Optical Coherence Tomography Angiography
      • Multifocal Electroretinography

     

    • Geographic Atrophy GA Market By Therapeutic Agents Clinical Phase (USD Billion, 2019-2035)

      • Late-Stage
      • Phase II
      • Phase I
      • Pre-Clinical Stage
      • Discovery Candidates

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials